Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival.
Francesca GiordanoGiuseppina Daniela NaimoAlessandra NigroFrancesco RomeoAlessandro PaolìFrancesca De AmicisAdele VivacquaCatia MorelliLoredana MauroMaria Luisa PannoPublished in: Drug design, development and therapy (2019)
Overall, our findings indicate that VPA in LNCaP prostate tumor cells, although it reduces cell proliferation, is able to drive neuroendocrine phenotype and to maintain the survival of these cells. Keeping in mind that neuroendocrine differentiation of prostate cancer appears to be associated with a poor prognosis, it is necessary to develop new treatments that do not induce neurodifferentiation but able to counteract cell survival.